- Home
- CAG vs BBIO Comparison
CAG vs BBIO Comparison
Compare CAG & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAG
- BBIO
- Stock Information
- Founded
- CAG 1919
- BBIO 2015
- Country
- CAG United States
- BBIO United States
- Employees
- CAG N/A
- BBIO N/A
- Industry
- CAG Packaged Foods
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CAG Consumer Staples
- BBIO Health Care
- Exchange
- CAG Nasdaq
- BBIO Nasdaq
- Market Cap
- CAG 9.3B
- BBIO 9.4B
- IPO Year
- CAG N/A
- BBIO 2019
- Fundamental
- Price
- CAG $19.18
- BBIO $51.21
- Analyst Decision
- CAG Hold
- BBIO Strong Buy
- Analyst Count
- CAG 11
- BBIO 16
- Target Price
- CAG $21.73
- BBIO $64.44
- AVG Volume (30 Days)
- CAG 11.3M
- BBIO 2.2M
- Earning Date
- CAG 10-01-2025
- BBIO 11-11-2025
- Dividend Yield
- CAG 7.30%
- BBIO N/A
- EPS Growth
- CAG 233.33
- BBIO N/A
- EPS
- CAG 2.40
- BBIO N/A
- Revenue
- CAG $11,612,800,000.00
- BBIO $235,812,000.00
- Revenue This Year
- CAG N/A
- BBIO $115.49
- Revenue Next Year
- CAG N/A
- BBIO $64.61
- P/E Ratio
- CAG $7.99
- BBIO N/A
- Revenue Growth
- CAG N/A
- BBIO 7.62
- 52 Week Low
- CAG $18.19
- BBIO $21.72
- 52 Week High
- CAG $33.04
- BBIO $54.60
- Technical
- Relative Strength Index (RSI)
- CAG 48.50
- BBIO 52.92
- Support Level
- CAG $19.03
- BBIO $52.20
- Resistance Level
- CAG $19.59
- BBIO $54.60
- Average True Range (ATR)
- CAG 0.43
- BBIO 2.26
- MACD
- CAG 0.05
- BBIO -0.06
- Stochastic Oscillator
- CAG 57.52
- BBIO 56.48
About CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.